Intel stock spikes after report of possible US government stake
PHOENIX - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), whose stock has declined nearly 13% in the past week according to InvestingPro data, announced Thursday it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application focused on treating Type 1 diabetes through cell-based immunotherapy.
The patent, titled "Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity," will remain in effect until at least 2040 once granted. It covers the company’s ImmCelz product, which utilizes supercharged T regulatory cells. The company, which InvestingPro analysis suggests is currently undervalued, maintains a strong balance sheet with more cash than debt.
Type 1 diabetes is an autoimmune disease where the body’s immune system attacks insulin-producing beta cells in the pancreas, leading to insulin deficiency.
The ImmCelz platform works by extracting a patient’s immune cells, reprogramming them outside the body with cell-free factors, and then re-injecting them into the same patient. According to the company, this process provides the cells with regenerative properties while maintaining their original functions.
"We believe that the use of ImmCelz to prevent and/or treat Type 1 Diabetes is regenerative immunotherapy in its truest form," said Timothy Warbington, CEO of Creative Medical Technology Holdings, in a press release statement.
The company is currently conducting a CREATE-1 clinical trial focused on Type 1 diabetes treatment.
Creative Medical Technology Holdings specializes in regenerative medicine with applications in pain management, neurology, and urology. With a market capitalization of $6.45 million and a Fair overall financial health rating from InvestingPro, the company shows potential despite its current unprofitable status.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.